Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer

Nutrition and Cancer

Volumn 63, Issue 8, 2011, Pages 1287-1296

  Huang, E Chu ^a   Chen, Guoxun ^a   Baek, Seung Joon ^a   McEntee, Michael F ^a   Collier, J Jason ^a   Minkin, Steven ^a   Biggerstaff, John ^a   Whelan, Jay ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HERBACEOUS AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ZYFLAMEND;

ADENOVIRUS INFECTION; ARTICLE; CASTRATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84863115866     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.606956     Document Type: Article

References (29)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin 58, 71-96, 2008.
2. Hsing AW, Tsao L, and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85, 60-67, 2000.
3. Schulze H and Senge T: Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 144, 934-941, 1990. (Pubitemid 20324827)
4. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, and Scarpelli M: Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 4, 321-332, 2007. (Pubitemid 46901993)
5. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 7, 43-51, 2009.
6. Yang P, Cartwright C, Chan D, vijjeswarapu M, Ding J, et al. Zyflamendmediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther 6, 228-236, 2007. (Pubitemid 46641627)
7. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, and Buttyan R: Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer 52, 202-212, 2005. (Pubitemid 41579762)
8. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332, 1393-1398, 1995.
9. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61, 2892-2898, 2001. (Pubitemid 32691931)
10. Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12, 1665-1671, 2006.
11. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Re. Cancer 1, 34-45, 2001. (Pubitemid 33741879)
12. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92, 1910-1917, 2000.
13. Culig Z, HobischA, CronauerM., Radmayr C, Trapman J, et al.Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor- I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54, 5474-5478, 1994.
14. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, et al. Upregulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 36, 1186-1196, 2005. (Pubitemid 41540395)
15. Paliouras M and Diamandis EP: An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell linesv Biol Chem 389, 773-780, 2008. (Pubitemid 352009405)
16. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. JBiol Chem282, 7329-7338, 2007. (Pubitemid 47093686)
17. Yanase T and FanW:Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma. vitam Horm 80, 649-666, 2009.
18. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, et al. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 148, 2984-2993, 2007. (Pubitemid 46984806)
19. Fujio Y, GuoK,ManoT,Mitsuuchi Y,Testa JR, et al.Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol 19, 5073-5082, 1999. (Pubitemid 29289545)
20. Donovan MJ, Osman I, Khan FM, .engrenyuk Y, Capodieci P, et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 105, 462-467, 2010.
21. Kojima S, Inahara M, Suzuki H, Ichikawa T, and Furuya Y: Implications of insulin-like growth factor-I for prostate cancer therapiesv Int J Urol 16, 161-167, 2009.
22. Ghosh PM, Malik S, Bedolla R, and Kreisberg JI: Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 4, 487-496, 2003. (Pubitemid 37536869)
23. Plymate SR,TennantMK,Culp SH,WoodkeL,Marcelli M, et al.Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 61, 276-290, 2004. (Pubitemid 39350451)
24. Lin HK, Wang L, Hu YC, Altuwaijri S, and Chang C: Phosphorylationdependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21, 4037-4048, 2002. (Pubitemid 34857436)
25. Mikhailova M,Wang Y, Bedolla R, Lu XH, Kreisberg JI, et al. AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Ad. Exp Med Biol 617, 397-405, 2008.
26. Shi XB, Ma AH, Xia L, Kung HJ, and de .ere White RW: Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62, 1496-1502, 2002. (Pubitemid 34407813)
27. Zhao XY, Malloy PJ, Krishnan A., Swami S, Navone NM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6, 703-706, 2000. (Pubitemid 30398797)
28. McDonald S, Brive L, Agus DB, Scher HI, and Ely KR: Ligand responsiveness in human prostate cancer: structural analysis ofmutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 60, 2317-2322, 2000. (Pubitemid 30262413)
29. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, et al. Characterization of a no.el androgen receptormutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62, 6606-6614, 2002. (Pubitemid 35364127)